Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial

Figures

• 

  FIGURE 1. Least squares mean change from baseline in right heart catheterisation parameters of a) mean pulmonary artery pressure (mPAP), b) pulmonary artery (PA) compliance, c) mean right atrial pressure (mRAP), and d) right ventricle (RV) work at week 24 presented by treatment group. Bars represent standard errors. **: p<0.0001, sotatercept versus placebo.

• 

  FIGURE 2. Least squares mean change from baseline in echocardiography parameters of a) tricuspid annular plane systolic excursion (TAPSE) to systolic pulmonary artery pressure (sPAP) ratio, b) right ventricular fractional area change (RVFAC), c) right ventricular area in end-diastole (RVA-ED), and d) right ventricular area in end-systole (RVA-ES) at week 24 presented by treatment group. Bars represent standard errors. **: p<0.0001, sotatercept versus placebo; *: p<0.050, sotatercept versus placebo.

• 

  FIGURE 3. Proportion of participants (%) with various tricuspid regurgitation degree ratings at baseline and week 24 presented by treatment group.

• 

  FIGURE 4. Scatterplots showing change from baseline in a) mean pulmonary artery pressure (mPAP), b) pulmonary vascular resistance (PVR), c) pulmonary artery (PA) elastance, and d) right ventricular area in end-systole (RVA-ES) and change from baseline in log2 of N-terminal pro-brain natriuretic peptide (NT-proBNP) at week 24. CC: correlation coefficient.

• 

  FIGURE 5. Scatterplots showing change from baseline in a) mean pulmonary artery pressure (mPAP), b) pulmonary vascular resistance (PVR), c) pulmonary artery (PA) elastance, d) cardiac efficiency (CE) and change from baseline in 6-min walk distance (6MWD) at week 24. CC: correlation coefficient.